ReviewLancet (London, England)2006
Clinical perspectives of emerging pathogens in bleeding disorders.
Review in Lancet (London, England), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.Blood transfusion = Trasfusione del sangue · 2014Guideline
- A paradigm shift in the detection of bloodborne pathogens: conventional approaches to recent detection techniques.EXCLI journal · 2024Review
- Article
- Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany.Risk management and healthcare policy · 2018Article
- Malaria and blood transfusion: major issues of blood safety in malaria-endemic countries and strategies for mitigating the risk of Plasmodium parasites.Parasitology research · 2016Review
- Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.Blood reviews · 2016Review
- Innovative approach for improved rFVIII concentrate.European journal of haematology · 2014Review
- Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.Haematologica · 2013Article
- Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?Transfusion · 2012Article
- Coagulation Factor IX for Hemophilia B Therapy.Acta naturae · 2012Article
- Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.Journal of blood medicine · 2012Article
- Review
- Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.International journal of hematology · 2009Review
- Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.Biotechnology journal · 2009Review
- Threat of dengue to blood safety in dengue-endemic countries.Emerging infectious diseases · 2009Article
- Pathogen safety of plasma-derived products - Haemate P/Humate-P.Haemophilia : the official journal of the World Federation of Hemophilia · 2008Review
- Blood safety and the choice of anti-hemophilic factor concentrate.Pediatric blood & cancer · 2006Review
- Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.Cardiology in reviewReview
- Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell lymphotropic virus. However, emerging pathogens could pose future threats, particularly those with blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better understanding of infectious diseases allows challenges from newly described agents of potential concern in the future to be anticipated, but the processes of zoonotic transmission and genetic selection or modification ensure that plasma-derived products will continue to be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the issue of emerging infectious agents by developing recombinant products that limit the need for human plasma during production. Such recombinant products have extended the safety profile of their predecessors by ensuring that all reagents used for cell culture, purification steps, and stabilisation and storage buffers are completely independent of human plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.